MetaCap

CG Oncology (CGON) vs Repligen (RGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CG Oncology (CGON) has outperformed Repligen (RGEN) over the past year, gaining 87.3% versus a gain of 0.8%. Repligen is the larger company by market cap ($10.47 billion vs $7.10 billion), about 1.5 times the size, while CG Oncology is growing revenue faster (+254.7% vs +16.4%). Repligen converts more of its revenue into profit, with a net margin of 6.6% versus -3985.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CGON+87.25%RGEN+0.80%
+107%+32%-44%
Nov 21, 20251 yearNov 20, 2026
CGON+126.86%RGEN-15.30%
+137%+38%-60%
Jan 22, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CGON versus RGEN key metrics
MetricCGONRGEN
Share price$79.47$163.81
Market cap$7.10B$10.47B
1-day change-2.97%-3.81%
YTD return+91.40%-0.03%
1-year return+87.25%+0.80%
5-year return—-42.73%
Forward P/E—61.77
EPS (TTM)$-2.76$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.04M$738.26M
Revenue growth (YoY)+254.70%+16.36%
Net income (latest FY)$-161.00M$48.89M
Gross margin—52.32%
Operating margin-4722.13%7.47%
Net margin-3985.02%6.62%
52-week high$93.95$198.87
52-week low$37.01$100.99
Distance from 52-week high-15.41%-17.63%
Analyst consensusstrong_buybuy
Avg. price target upside+38.03%+24.05%
Average volume1.24M1.17M
Shares outstanding89.32M63.92M
Employees1422,000
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CGON has outperformed RGEN by 86.5 percentage points over the past year.
  • Repligen is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -3985.0 cents for CG Oncology.
  • CG Oncology grew revenue faster in its latest fiscal year (+254.70% vs +16.36%).

About CG Oncology

CGON stock →

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees

About Repligen

RGEN stock →

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees

CGON vs RGEN FAQ

Which is bigger, CG Oncology or Repligen?

Repligen (RGEN) is larger, with a market capitalization of $10.47B compared with $7.10B for CG Oncology (CGON).

Which stock has performed better over the past year, CGON or RGEN?

CGON returned +87.25% over the past 12 months, compared with +0.80% for RGEN (price return, excluding dividends). Past performance does not predict future results.

Are CG Oncology and Repligen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons